Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Eisai Reshuffles R&D System to Speed Up Development of Anticancer Drugs
November 16, 2009
- Big Changes in Style of Discussions at Chuikyo
November 16, 2009
- Strong Yen Hit Top-Eight Domestic Companies’Performance
November 16, 2009
- Pricing Rule to Be Revised for New Products Containing Existing API: Chuikyo
November 16, 2009
- Half-Year Business Results of Domestic Companies: 2 （１）
November 16, 2009
- Share of Original Drugs Not Decreasing Much in Japan Despite Large Fall in Prices: Korosho Survey
November 16, 2009
- Half-Year Business Results of Domestic Companies: 2 （２）
November 16, 2009
- Korosho Considers Revising Medical Fees to Induce Doctors to Prescribe Fewer Antipsychotics
November 16, 2009
- 3 Societies Call For Vaccination of Girls Aged 11-14 with Cervarix
November 9, 2009
- Astellas Licenses MDV3100 for Prostate Cancer from Medivation
November 9, 2009
- PMDA Needs 2,000-3,000 Staff Members for Simultaneous Approval with US, EU: Chief Executive Kondo
November 9, 2009
- Japan Is the Most Important Market in Asia: Mr Barr of Covance
November 9, 2009
- Korosho Considers Extension of Tax Break on Research Expenses
November 9, 2009
- Takeda to Develop Global Business as “Medium-Sized Global Pharma”: Mr Hasegawa
November 9, 2009
- Japan Is Obliged to Promote Use of Generics: Dr Suzuki
November 9, 2009
- Medipal Aims at Sales of ¥30 Bil. in China in FY2012
November 9, 2009
- Dr Adachi Confirms ConservativeStance toward Industry Proposal
November 9, 2009
- Generic Amlodipine Comparable to Original Version: NPO Report
November 9, 2009
- Chuikyo Back to Work
November 9, 2009
- Daiichi Sankyo Applies for Injectable Levofloxacin on the Same Day as IP High Court Ruling
November 9, 2009
ページ
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…